Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for UNITED THERAPEUTICS Corp?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from $1.60B in FY2016 to $3.18B in FY2025 (9-year CAGR +7.9%).
- Net income was negative in FY2019.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 1.69 | 1.94 | 2.33 | 2.88 | 3.18 |
| YoY | 13.6% | 14.9% | 20.2% | 23.6% | 10.6% |
| Net Income (USD B) | 0.48 | 0.73 | 0.98 | 1.20 | 1.33 |
| YoY | -7.6% | 52.9% | 35.4% | 21.4% | 11.7% |
| Operating Cash Flow (USD B) | 0.60 | 0.80 | 0.98 | 1.33 | 1.56 |
| ROE | 12.9% | 16.6% | 18.3% | 19.2% | 19.7% |
| Gross Margin | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| Net Margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| Debt-to-Assets | 23.4% | 20.6% | 16.5% | 12.5% | 9.9% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 1.60 | 1.73 | 1.63 | 1.45 | 1.48 | 1.69 | 1.94 | 2.33 | 2.88 | 3.18 |
| YoY | — | 7.9% | -5.7% | -11.0% | 2.4% | 13.6% | 14.9% | 20.2% | 23.6% | 10.6% |
| Net Income (USD B) | 0.71 | 0.42 | 0.59 | -0.10 | 0.51 | 0.48 | 0.73 | 0.98 | 1.20 | 1.33 |
| YoY | — | -41.4% | 41.0% | -117.7% | — | -7.6% | 52.9% | 35.4% | 21.4% | 11.7% |
| Operating Cash Flow (USD B) | 0.64 | 0.47 | 0.78 | -0.21 | 0.76 | 0.60 | 0.80 | 0.98 | 1.33 | 1.56 |
| ROE | 38.6% | 21.1% | 24.1% | -3.8% | 16.7% | 12.9% | 16.6% | 18.3% | 19.2% | 19.7% |
| Gross Margin | 95.5% | 93.9% | 87.8% | 91.9% | 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| Net Margin | 44.6% | 24.2% | 36.2% | -7.2% | 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| Debt-to-Assets | 19.9% | 26.3% | 17.4% | 29.0% | 26.4% | 23.4% | 20.6% | 16.5% | 12.5% | 9.9% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Checked across financial quality, solvency, going concern, and SEC material filings (bankruptcy, delisting notice, auditor change, non-reliance, late filing) with no alerts or watch items triggered.
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.